Helmut Anderten1, Franz-Werner Dippel2, Karel Kostev3. 1. Office-Based Diabetologist, Hildesheim, Germany. 2. Sanofi-Aventis Deutschland GmbH, Berlin, Germany. 3. IMS HEALTH, Frankfurt, Germany kkostev@de.imshealth.com.
Abstract
AIMS: The aim was to compare early discontinuation and related treatment costs in type 2 diabetes in primary care after initiation of insulin glargine or human basal insulin (NPH). METHODS: Overall, 2765 glargine and 1554 NPH patients from 1072 general practices were analyzed (Disease Analyser). Early discontinuation was defined as switching to a different basal insulin or another insulin treatment regimen within 90 days after first basal insulin prescription (index date, ID). Treatment costs were assessed 365 days prior and post ID in both groups. Propensity score matching and linear regression was used to adjust cost differences (post vs prior ID: discontinued vs continued patients) for age, sex, diabetes duration, antidiabetic comedication, diabetologist care, disease management program participation, costs before ID, and Charlson Comorbidity Index. RESULTS: Within 3 months after ID, 13% of glargine patients switched to other insulin treatment regimens (NPH: 18%; P < .05). After propensity score matching, adjusted cost differences in 146 discontinued versus 1342 continued glargine patients were calculated (NPH: 146 vs 1342). Diabetes-related prescription costs were lower among persistent glargine patients compared to persistent NPH patients (EUR-49 [19]; P = .0109). Mean cost difference for diabetes-related prescriptions was lower among those who persisted on glargine compared to those who switched to other treatment regimens (EUR-74 [42], P = .0780). CONCLUSIONS: Treatment persistence within 3 months after basal insulin initiation was significantly higher under insulin glargine compared to NPH. Diabetes-related prescription costs were significantly lower among patients who adhered to insulin glargine compared to persistent NPH patients.
AIMS: The aim was to compare early discontinuation and related treatment costs in type 2 diabetes in primary care after initiation of insulinglargine or humanbasal insulin (NPH). METHODS: Overall, 2765 glargine and 1554 NPH patients from 1072 general practices were analyzed (Disease Analyser). Early discontinuation was defined as switching to a different basal insulin or another insulin treatment regimen within 90 days after first basal insulin prescription (index date, ID). Treatment costs were assessed 365 days prior and post ID in both groups. Propensity score matching and linear regression was used to adjust cost differences (post vs prior ID: discontinued vs continued patients) for age, sex, diabetes duration, antidiabetic comedication, diabetologist care, disease management program participation, costs before ID, and Charlson Comorbidity Index. RESULTS: Within 3 months after ID, 13% of glarginepatients switched to other insulin treatment regimens (NPH: 18%; P < .05). After propensity score matching, adjusted cost differences in 146 discontinued versus 1342 continued glarginepatients were calculated (NPH: 146 vs 1342). Diabetes-related prescription costs were lower among persistent glarginepatients compared to persistent NPH patients (EUR-49 [19]; P = .0109). Mean cost difference for diabetes-related prescriptions was lower among those who persisted on glargine compared to those who switched to other treatment regimens (EUR-74 [42], P = .0780). CONCLUSIONS: Treatment persistence within 3 months after basal insulin initiation was significantly higher under insulinglargine compared to NPH. Diabetes-related prescription costs were significantly lower among patients who adhered to insulinglargine compared to persistent NPH patients.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Peter Mullins; Peter Sharplin; Hannele Yki-Jarvinen; Matthew C Riddle; Hans-Ulrich Haring Journal: Clin Ther Date: 2007-08 Impact factor: 3.393
Authors: Reinhard G Bretzel; Ulrike Nuber; Wolfgang Landgraf; David R Owens; Clare Bradley; Thomas Linn Journal: Lancet Date: 2008-03-29 Impact factor: 79.321
Authors: Juliana C N Chan; Juan José Gagliardino; Hasan Ilkova; Fernando Lavalle; Ambady Ramachandran; Jean Claude Mbanya; Marina Shestakova; Cecile Dessapt-Baradez; Jean-Marc Chantelot; Pablo Aschner Journal: Adv Ther Date: 2021-05-12 Impact factor: 3.845
Authors: Aida Moreno-Juste; Beatriz Poblador-Plou; Mercedes Aza-Pascual-Salcedo; Francisca González-Rubio; Sara Malo; Julián Librero López; Victoria Pico-Soler; Eva Giménez Labrador; Sara Mucherino; Valentina Orlando; Enrica Menditto; Alexandra Prados-Torres; Antonio Gimeno-Miguel Journal: Int J Environ Res Public Health Date: 2020-05-25 Impact factor: 3.390